314 related articles for article (PubMed ID: 23294063)
21. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.
van Helden PM; van den Berg HM; Gouw SC; Kaijen PH; Zuurveld MG; Mauser-Bunschoten EP; Aalberse RC; Vidarsson G; Voorberg J
Br J Haematol; 2008 Aug; 142(4):644-52. PubMed ID: 18510679
[TBL] [Abstract][Full Text] [Related]
22. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.
Oldenburg J; Austin SK; Kessler CM
Haemophilia; 2014 Sep; 20 Suppl 6():17-26. PubMed ID: 24975701
[TBL] [Abstract][Full Text] [Related]
23. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
24. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?
Ettingshausen CE; Kreuz W
Haemophilia; 2013 Jan; 19 Suppl 1():12-7. PubMed ID: 23278995
[TBL] [Abstract][Full Text] [Related]
25. Immune tolerance induction rescue with turoctocog-alfa in a poor risk haemophilia A inhibitor young child: the history of a success.
Zanon E; Milan M; Pasca S
Blood Coagul Fibrinolysis; 2018 Jul; 29(5):465-468. PubMed ID: 29652676
[TBL] [Abstract][Full Text] [Related]
26. [Immune tolerance induction with high-dose FVIII and pulsed intravenous immunoglobulin].
Stiefel M; Pinkwart C; Haase R; Merkel N; Forsberg D; Mauz-Körholz C
Hamostaseologie; 2010 Nov; 30 Suppl 1():S119-21. PubMed ID: 21042665
[TBL] [Abstract][Full Text] [Related]
27. Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution?
Di Minno G; Coppola A
Haemophilia; 2013 Jan; 19 Suppl 1():18-23. PubMed ID: 23278996
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma-derived FVIII/VWF product: the long-term ITI study.
Jiménez-Yuste V; Oldenburg J; Rangarajan S; Peiró-Jordán R; Santagostino E
Haemophilia; 2016 Nov; 22(6):859-865. PubMed ID: 27329267
[TBL] [Abstract][Full Text] [Related]
29. Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success.
Elalfy M; Elghamry I; Hassab H; Elalfy O; Andrawes N; El-Ekiaby M
Haemophilia; 2022 Jan; 28(1):65-72. PubMed ID: 34797008
[TBL] [Abstract][Full Text] [Related]
30. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
31. The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance induction.
Caram C; de Souza RG; de Sousa JC; Araújo Pereira T; do Amaral Cerqueira AM; van der Bom JG; Rezende SM
Thromb Haemost; 2011 Jan; 105(1):59-65. PubMed ID: 21057702
[TBL] [Abstract][Full Text] [Related]
32. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
33. Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.
Mizoguchi Y; Furue A; Kagawa R; Chijimatsu I; Tomioka K; Shimomura M; Imanaka Y; Nishimura S; Saito S; Miki M; Ono A; Konishi N; Kawaguchi H; Kobayashi M
Int J Hematol; 2016 Apr; 103(4):473-7. PubMed ID: 26830966
[TBL] [Abstract][Full Text] [Related]
34. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
[TBL] [Abstract][Full Text] [Related]
35. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors.
Kurth MA; Dimichele D; Sexauer C; Sanders JM; Torres M; Zappa SC; Ragni M; Leonard N
Haemophilia; 2008 Jan; 14(1):50-5. PubMed ID: 17941829
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.
Abbonizio F; Giampaolo A; Coppola A; ; Arcieri R; Hassan HJ
Haemophilia; 2014 Jul; 20(4):e243-50. PubMed ID: 24834967
[TBL] [Abstract][Full Text] [Related]
37. Low prevalence of inhibitor antibodies in the Canadian haemophilia population.
Webert KE; Rivard GE; Teitel J; Carcao M; Lillicrap D; St-Louis J; Walker IR
Haemophilia; 2012 May; 18(3):e254-9. PubMed ID: 22077390
[TBL] [Abstract][Full Text] [Related]
38. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors.
van Helden PM; Van Haren SD; Fijnvandraat K; van den Berg HM; Voorberg J
Haemophilia; 2010 May; 16(102):35-43. PubMed ID: 20536984
[TBL] [Abstract][Full Text] [Related]
39. Immune tolerance induction in patients with hemophilia A.
Astermark J
Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
[TBL] [Abstract][Full Text] [Related]
40. Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study.
Antun A; Monahan PE; Manco-Johnson MJ; Callaghan MU; Kanin M; Knoll C; Carpenter SL; Davis JA; Guerrera MF; Kruse-Jarres R; Ragni MV; Witmer C; McCracken CE; Kempton CL
J Thromb Haemost; 2015 Nov; 13(11):1980-8. PubMed ID: 26382916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
